Rimonabant: A Cannabinoid Receptor Type 1 Blocker for Management of Multiple Cardiometabolic Risk Factors

Rimonabant: A Cannabinoid Receptor Type 1 (CB1) Blocker for Management of Multiple Cardiometabolic Risk Factors Eli V. Gelfand, Christopher P. Cannon Rimonabant is a selective blocker of the cannabinoid CB1receptors being developed for the treatment first of multiple cardiometabolic risk factors, including obesity and smoking. Large trials have shown that rimonabant, when compared with placebo, leads to greater weight loss, favorable changes in serum lipid levels, an improvement in glycemic control in type 2 diabetes, and increased smoking quit rates. Rimonabant is well tolerated, with a primary side effect of mild nausea. As an agent with a novel mechanism of action, rimonabant has a potential to be a useful adjunct to lifestyle modification in treatment of multiple cardiometabolic risk factors, including obesity and smoking. Rimonabant is a first selective blocker of the cannabinoid receptor type 1 (CB1) being developed for the treatment of multiple cardiometabolic risk factors, including abdominal obesity and smoking. In four large trials, after one year of treatment, rimonabant 20 mg led to greater weight loss and reduction in waist circumference compared with placebo. Therapy with rimonabant is also associated with favorable changes in serum lipid levels and an improvement in glycemic control in prediabetes patients and in type 2 diabetic patients. At the same dose, rimonabant significantly increased cigarette smoking quit rates as compared with placebo. Rimonabant seems to be well tolerated, with a primary side effect of mild nausea. As an agent with a novel mechanism of action, rimonabant has a potential to be a useful adjunct to lifestyle and behavior modification in treatment of multiple cardiometabolic risk factors, including abdominal obesity and smoking.